| Basics |
Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company. The company is engaged in discovering or licensing, developing and commercializing proprietary therapeutics in the fields of oncology, autoimmune and infectious diseases.
|
| IPO Date: |
September 20, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.16B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.20 | 2.47%
|
| Avg Daily Range (30 D): |
$0.31 | 1.32%
|
| Avg Daily Range (90 D): |
$0.45 | 1.50%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.44M |
| Avg Daily Volume (30 D): |
.86M |
| Avg Daily Volume (90 D): |
.65M |
| Trade Size |
| Avg Trade Size (Sh.): |
74 |
| Avg Trade Size (Sh.) (30 D): |
85 |
| Avg Trade Size (Sh.) (90 D): |
71 |
| Institutional Trades |
| Total Inst.Trades: |
3,325 |
| Avg Inst. Trade: |
$2.54M |
| Avg Inst. Trade (30 D): |
$1.91M |
| Avg Inst. Trade (90 D): |
$2.15M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.68M |
| Avg Closing Trade (30 D): |
$1.27M |
| Avg Closing Trade (90 D): |
$1.86M |
| Avg Closing Volume: |
50.01K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$-.03
|
$-.04
|
|
Diluted EPS
|
|
$-.03
|
$-.04
|
|
Revenue
|
$
|
$ 116.1M
|
$ 109.98M
|
|
Gross Profit
|
$
|
$ 69.33M
|
$ 66.97M
|
|
Net Income / Loss
|
$
|
$ -35.96M
|
$ -40.73M
|
|
Operating Income / Loss
|
$
|
$ -48.82M
|
$ -54.9M
|
|
Cost of Revenue
|
$
|
$ 46.76M
|
$ 43M
|
|
Net Cash Flow
|
$
|
$ -15.3M
|
$ -25.1M
|
|
PE Ratio
|
|
|
|
|
|
|
